Recursion Pharmaceuticals: Stock Unresponsive To Clinical Updates (NASDAQ:RXRX)

Recursion Pharmaceuticals ( RXRX ) provided clinical updates from two of its programs in late 2025, but the company's stock hasn't mounted a sustained rally. In my previous article in August 2025, I rated the stock a sell, noting that whileScientist and trader of biotech stock. Focus on trading around events such as trial results and NDA/BLA approvals. Also covering companies in industries regulated by the FDA. Articles present my opinion on stocks, but don't constitute investment advice.Analyst’s Disclosur ...